CIA
KYNB

CSat Investment Advisory’s Kyntra Bio KYNB Stock Holding History

CSat Investment Advisory’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14
Closed -$14K – 675
2020
Q3 		$14K Buy
14
+2
+17% +$2.15K ﹤0.01% 962
2020
Q2 		$12K Buy
12
+2
+20% +$1.86K ﹤0.01% 986
2020
Q1 		$9K Buy
10
+2
+25% +$1.99K ﹤0.01% 937
2019
Q4 		$9K Buy
8
+1
+14% +$1.02K ﹤0.01% 1006
2019
Q3 		$7K Buy
7
+1
+17% +$1.1K ﹤0.01% 1003
2019
Q2 		$7K Buy
+6
New +$6.57K ﹤0.01% 993

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CSat Investment Advisory's KYNB Position: Q4 2020 in Review

CSat Investment Advisory sold out of Kyntra Bio (KYNB) in Q4 2020, closing a stake of 14 shares — an estimated $14K sold.

CSat Investment Advisory first reported a position in KYNB in Q2 2019 and held it in 6 quarters. The position peaked at $14K in Q3 2020. 207 funds tracked by Wall St. Rank hold KYNB as of Q4 2020.

  • CSat Investment Advisory reported no remaining Kyntra Bio position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 14 Kyntra Bio shares in Q4 2020, an estimated $14K.
  • CSat Investment Advisory first reported a position in Kyntra Bio in Q2 2019 and held it in 6 quarters.
  • CSat Investment Advisory's Kyntra Bio position peaked at $14K in Q3 2020.
  • 207 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.